The Latest Cardiac and Vascular News
ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. Financial Highlights: Revenue of $204.0 million for the fourth quarter of 2021, an increase of 22.2% compared to revenue of $166.9 million for the fourth quarter […]
Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions WAYNE, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and […]
SUZHOU, China, Feb. 23, 2022 /PRNewswire/ — SyMap Medical Ltd. (Suzhou, China) announced successful completion of enrollment in the company’s SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811), using the SyMapCath I™ Catheter/SYMPIONEER S1™ Mapping/RF System for the treatment of uncontrolled hypertension. This is the first pivotal study for registration purpose, worldwide, using […]
ARTARMON, Australia, Feb. 23, 2022 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced the appointment of Doug Godshall as Chairman of its Board […]
Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive […]
MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock […]
On-site plant will produce DEFINITY® (Perflutren Lipid Microsphere), the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial […]
HOUSTON–(BUSINESS WIRE)–Saranas, a company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, announced today that the U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414. Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding […]
Mechanical and aspiration devices to treat peripheral vascular disease, deep vein thrombosis and pulmonary embolism ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today it has partnered with Innova […]
Former Johnson & Johnson, Auris Health, and Intuitive Surgical Exec to Lead Eko’s Commercial Expansion OAKLAND, Calif., Feb. 23, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced the appointment of Eric Davidson as President and Chief Operating Officer. Davidson joins Eko from Johnson & Johnson, where he […]
